Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing

NCT03433833 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT03433833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03433833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing
Lead sponsor
University of Illinois at Chicago
Phase
Phase 1
Overall status
Withdrawn
Start date
November 10, 2019
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chuvash erythrocytosis, erythrocytosis; familial, hif-2alpha erythrocytosis, phd2 erythrocytosis, polycythemia; familial, vhl gene mutation